248 related articles for article (PubMed ID: 27698099)
1. BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
Pullarkat VA; Newman EM
Cancer Discov; 2016 Oct; 6(10):1082-1083. PubMed ID: 27698099
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
Pfeiffer T; Li Y; Ashcraft E; Karol SE; Rubnitz JE; Epperly R; Madden R; Mamcarz E; Obeng E; Qudeimat A; Sharma A; Srinivasan A; Suliman A; Talleur AC; Velasquez MP; Gottschalk S; Triplett BM; Naik S
Bone Marrow Transplant; 2023 Mar; 58(3):328-331. PubMed ID: 36443431
[No Abstract] [Full Text] [Related]
4. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Konopleva M; Pollyea DA; Potluri J; Chyla B; Hogdal L; Busman T; McKeegan E; Salem AH; Zhu M; Ricker JL; Blum W; DiNardo CD; Kadia T; Dunbar M; Kirby R; Falotico N; Leverson J; Humerickhouse R; Mabry M; Stone R; Kantarjian H; Letai A
Cancer Discov; 2016 Oct; 6(10):1106-1117. PubMed ID: 27520294
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
6. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
Byrne M; Danielson N; Sengsayadeth S; Rasche A; Culos K; Gatwood K; Wyatt H; Chinratanalab W; Dholaria B; Ferrell PB; Fogo K; Goodman S; Jagasia M; Jayani R; Kassim A; Mohan SR; Savani BN; Strickland SA; Engelhardt BG; Savona M
Am J Hematol; 2020 Sep; 95(9):1006-1014. PubMed ID: 32390196
[TBL] [Abstract][Full Text] [Related]
7. Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.
Ashby M; Fleming S; Teh TC; Tiong IS; Inam S; Curtis DJ; Patil S; Vassili C; Chua CC
Leuk Res; 2024 Jan; 136():107429. PubMed ID: 38008060
[No Abstract] [Full Text] [Related]
8. Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.
Flores-Jiménez JA; Pimentel-Morales MA; González-Ramella O; Vega-Cortés D; Zambrano-Velarde MÁ
J Adolesc Young Adult Oncol; 2019 Aug; 8(4):481-483. PubMed ID: 30835153
[TBL] [Abstract][Full Text] [Related]
9. [What is recommended in the treatment of acute myeloid leukemia?].
Thol F
Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
[TBL] [Abstract][Full Text] [Related]
10. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
Bewersdorf JP; Derkach A; Gowda L; Menghrajani K; DeWolf S; Ruiz JD; Ponce DM; Shaffer BC; Tamari R; Young JW; Jakubowski AA; Gyurkocza B; Chan A; Xiao W; Glass J; King AC; Cai SF; Daniyan A; Famulare C; Cuello BM; Podoltsev NA; Roshal M; Giralt S; Perales MA; Seropian S; Cho C; Zeidan AM; Prebet T; Stein EM; Tallman MS; Goldberg AD; Stahl M
Leuk Lymphoma; 2021 Dec; 62(14):3394-3401. PubMed ID: 34477024
[TBL] [Abstract][Full Text] [Related]
12. Can we selectively target AML stem cells?
Jordan CT
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
[TBL] [Abstract][Full Text] [Related]
13. Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.
Wang J; Zhu H; Miao K
Ann Hematol; 2024 May; 103(5):1775-1777. PubMed ID: 38556531
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
[No Abstract] [Full Text] [Related]
15. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.
Joshi M; Cook J; McCullough K; Nanaa A; Gangat N; Foran JM; Murthy HS; Kharfan-Dabaja MA; Sproat L; Palmer J; Pardanani A; Tefferi A; Begna K; Elliot M; Al-Kali A; Patnaik M; Shah MV; Hogan WJ; Litzow MR; Alkhateeb HB
Blood Cancer J; 2021 Mar; 11(3):49. PubMed ID: 33664234
[No Abstract] [Full Text] [Related]
16. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.
Han L; Zhang Q; Dail M; Shi C; Cavazos A; Ruvolo VR; Zhao Y; Kim E; Rahmani M; Mak DH; Jin SS; Chen J; Phillips DC; Koller PB; Jacamo R; Burks JK; DiNardo C; Daver N; Jabbour E; Wang J; Kantarjian HM; Andreeff M; Grant S; Leverson JD; Sampath D; Konopleva M
Haematologica; 2020 Mar; 105(3):697-707. PubMed ID: 31123034
[TBL] [Abstract][Full Text] [Related]
17. Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation.
Abou Dalle I; Bazarbachi A
Bone Marrow Transplant; 2021 Nov; 56(11):2626-2627. PubMed ID: 34376805
[No Abstract] [Full Text] [Related]
18. [Successful treatment with venetoclax and demethylation drugs in one acute myeloid leukemia patient relapsed after cord blood stem cell transplantation: a case report and literature review].
Tong J; Yao W; Liu HL; Zheng CC; Geng LQ; Zuo XY; Tang BL; Wan X; Zhou L; Song KD; Zhang XH; Sun ZM
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1050-1051. PubMed ID: 32023741
[No Abstract] [Full Text] [Related]
19. Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.
Sato H; Kobayashi T; Fujita N; Yamashita T; Kitadate A; Yoshioka T; Nara M; Kameoka Y; Miura M; Takahashi N
Cancer Chemother Pharmacol; 2022 Sep; 90(3):279-284. PubMed ID: 35962819
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax for Refractory Myeloid Sarcoma.
Kanate AS; Vos J; Chargualaf MJ
J Oncol Pract; 2019 Jul; 15(7):413-415. PubMed ID: 31291562
[No Abstract] [Full Text] [Related]
[Next] [New Search]
